Your browser doesn't support javascript.
loading
Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy.
Sweeney, Christopher J; Martin, Andrew J; Stockler, Martin R; Begbie, Stephen; Chi, Kim N; Chowdhury, Simon; Coskinas, Xanthi; Frydenberg, Mark; Hague, Wendy E; Horvath, Lisa G; Joshua, Anthony M; Lawrence, Nicola J; Marx, Gavin M; McCaffrey, John; McDermott, Ray; McJannett, Margaret; North, Scott A; Parnis, Francis; Parulekar, Wendy; Pook, David W; Reaume, M Neil; Sandhu, Shahneen K; Tan, Alvin; Tan, Thean Hsiang; Thomson, Alastair; Tu, Emily; Vera-Badillo, Francisco; Williams, Scott G; Yip, Sonia; Zhang, Alison Y; Zielinski, Robert R; Davis, Ian D.
Afiliação
  • Sweeney CJ; Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: christopher_sweeney@dfci.harvard.edu.
  • Martin AJ; NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia.
  • Stockler MR; NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia; Concord Cancer Centre, Concord Repatriation General Hospital, Concord, Australia; Chris O'Brien Lifehouse RPA, Sydney, Australia.
  • Begbie S; Port Macquarie Base Hospital, Port Macquarie, NSW, Australia; Mid North Coast Cancer Institute Port Macquarie, Port Macquarie, NSW, Australia.
  • Chi KN; BC Cancer Agency, Vancouver, BC, Canada; University of British Columbia, Vancouver, BC, Canada.
  • Chowdhury S; Guy's and St Thomas' NHS Foundation Trust Biomedical Research Centre, CRUK and King's College London, UK; Sarah Cannon Research UK, London, UK.
  • Coskinas X; NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia.
  • Frydenberg M; Monash University, Melbourne, Australia; Australian Urology Associates, Melbourne, Australia.
  • Hague WE; NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia.
  • Horvath LG; Chris O'Brien Lifehouse RPA, Sydney, Australia; University of Sydney, Sydney, Australia.
  • Joshua AM; Kinghorn Cancer Centre, St Vincents Hospital, Sydney, Australia; Garvan Institute of Medical Research, Sydney, Australia.
  • Lawrence NJ; Auckland City Hospital, Auckland, New Zealand.
  • Marx GM; University of Sydney, Sydney, Australia; Sydney Adventist Hospital, Wahroonga, Australia.
  • McCaffrey J; Cancer Trials Ireland, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland.
  • McDermott R; Cancer Trials Ireland, Dublin, Ireland; St. Vincent's University Hospital, Dublin, Ireland; University College Dublin, Ireland.
  • McJannett M; ANZUP Cancer Trials Group, Australia.
  • North SA; Cross Cancer Institute, Edmonton, AB, Canada; University of Alberta, Edmonton, AB, Canada.
  • Parnis F; Adelaide Cancer Centre, Adelaide, Australia; University of Adelaide, Adelaide, Australia.
  • Parulekar W; Canadian Cancer Trials Group (CCTG) Queen's University, Kingston, ON, Canada.
  • Pook DW; Monash University, Melbourne, Australia; Monash Health, Melbourne, Australia.
  • Reaume MN; University of Ottawa, Ottawa, ON, Canada; Ottawa Hospital Research Institute, Ottawa, ON, Canada.
  • Sandhu SK; Peter MacCallum Cancer Centre, Melbourne, Australia; University of Melbourne, Melbourne, Australia.
  • Tan A; Waikato District Health Board, Hamilton, New Zealand.
  • Tan TH; Royal Adelaide Hospital, Adelaide, Australia.
  • Thomson A; Royal Cornwall Hospital, Truro, Cornwall, UK.
  • Tu E; NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia.
  • Vera-Badillo F; Kingston Health Sciences Center, Kingston, ON, Canada; Canadian Cancer Trials Group, Kingston, ON, Canada.
  • Williams SG; Peter MacCallum Cancer Centre, Melbourne, Australia; University of Melbourne, Melbourne, Australia.
  • Yip S; NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia.
  • Zhang AY; NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia; Chris O'Brien Lifehouse RPA, Sydney, Australia; Macquarie University, Sydney, Australia.
  • Zielinski RR; Orange Health Service, Central West Cancer Care Centre, Orange, Australia; Western Sydney University, Sydney, Australia.
  • Davis ID; Monash University, Melbourne, Australia; Eastern Health, Melbourne, Australia.
Eur Urol ; 80(3): 275-279, 2021 09.
Article em En | MEDLINE | ID: mdl-34030924
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Feniltioidantoína / Neoplasias da Próstata / Tioidantoínas / Benzamidas / Segunda Neoplasia Primária / Antagonistas de Androgênios / Antineoplásicos / Nitrilas Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans / Male Idioma: En Revista: Eur Urol Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Feniltioidantoína / Neoplasias da Próstata / Tioidantoínas / Benzamidas / Segunda Neoplasia Primária / Antagonistas de Androgênios / Antineoplásicos / Nitrilas Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans / Male Idioma: En Revista: Eur Urol Ano de publicação: 2021 Tipo de documento: Article